Kenvue announces FDA approval of TYLENOL with Naproxen
This first OTC fixed-dose combo of acetaminophen and naproxen sodium offers new opioid-free pain relief option
See the latest news and media coverage for Kenvue. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global consumer health company
kenvue.comLast updated
In short: Kenvue secured FDA approval for a new Tylenol combination pill and agreed to a $48.7 billion acquisition by Kimberly-Clark.
This first OTC fixed-dose combo of acetaminophen and naproxen sodium offers new opioid-free pain relief option
The company's Healthy Lives Mission Report shows progress in emissions reduction and renewable energy.
The FDA order issued June 10, 2026, allows BEMT use in US sunscreens effective Aug 9, 2026.
Net sales grew 4.5% to $3.9B, organic sales up 0.7%, adjusted diluted EPS up 33% to $0.32.
Kenvue Inc. KVUE is slated to report second-quarter 2026 results on Aug. 6, before market open. The company is likely to report top and bottom-line...
Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents...
On July 24, 2026, Kenvue Inc (KVUE) announced the FDA's approval of a groundbreaking product:...
July 24 (Reuters) - The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that ...
Track Kenvue and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kenvue and other trending companies.